Page 11 - Double Blind Study News Today

The drug was a boon for many patients, mainly those with moderate to severe disease, but cost and insurance approvals posed challenges.

Lifileucel is the first cellular therapy to be approved to treat patients with unresectable or metastatic melanoma.

The study is thought to be the first comprehensive analysis to evaluate NMRF as a treatment for acne, according to the authors.

Among older adults with normal blood pressure, replacing table salt with salt substitute reduced the incidence of hypertension vs a usual salt group, in the DECIDE-Salt trial.

In patients presenting at thrombectomy-capable stroke centers, the benefit associated with thrombolysis before thrombectomy was time dependent, new data suggested.

Adults with resistant schizophrenia have significant gut microbiome differences vs their counterparts who respond to treatment, a new finding that may be driven by clozapine treatment.

In patients with SUD, even slight reductions in drug use are linked to better outcomes, suggesting abstinence should not be the only goal of treatment, a new analysis showed.

More than 2 years after its controversial accelerated FDA approval, Biogen says it will halt development and commercialization of aducanumab and focus on lecanemab.

Once-weekly insulin icodec reduced A1c levels the same or better than once-daily glargine and degludec.

Vienna researchers reported that 7 of 10 patients treated with systemic sirolimus had noted improvements in skin lesions, which continued for up to 2 years of follow-up.